The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin.
With the increased use of immunoglobulin for intravenous use (IGIV) as replacement therapy for patients with primary immunodeficiencies, a natural concern is whether such preparations demonstrate a normal turnover rate with regard to total IgG, individual IgG subclasses, and specific antibody titers. We have conducted such a pharmacokinetic study on a cohort of eight patients with an IGIV preparation, Gammagard. For total IgG, the half-life found was 25.8 days; for IgG1 it was 29.7 days; for IgG2 it was 26.9 days; and for IgG3 it was 15.7 days. The results are similar to those reported for endogeneous IgG. Half-lives for antibodies to S. minnesota (Re 595 mutant), cytomegalovirus, and S. pneumoniae were of the same order of magnitude as that for total IgG. We conclude that this IGIV preparation is catabolized in patients with primary immunodeficiency at a rate similar to that of native IgG in normal individuals.
Mankarious
S
S
Hyland Division of Baxter Healthcare Corp., Glendale, CA.
Lee
M
M
Fischer
S
S
Pyun
K H
KH
Ochs
H D
HD
Oxelius
V A
VA
Wedgwood
R J
RJ
D000293:Adolescent; D000328:Adult; D000368:Aged; D000906:Antibodies / Q000032:analysis*; D002648:Child; D006207:Half-Life; D006801:Humans; D007116:Immunization, Passive; D007074:Immunoglobulin G / Q000145:classification / Q000378:metabolism*; D007153:Immunologic Deficiency Syndromes / Q000276:immunology / Q000378:metabolism / Q000628:therapy*; D008875:Middle Aged
D000906:Antibodies; D007074:Immunoglobulin G